| $385M | ||
| $350M | ||
| $215M | ||
| $88M | ||
| $82M | ||
| $62M |
Buys | $14,999,931 | 3 | 33 |
Sells | $371,052 | 6 | 67 |
| ARCH Venture Partners X, LLC | 10 percent owner | 1 | $5M | 0 | $0 | $5M |
| ARCH Venture Partners XII, LLC | 10 percent owner | 1 | $5M | 0 | $0 | $5M |
| Burow Kristina | 1 | $5M | 0 | $0 | $5M | |
| Milligan Michael Lee | See Remarks | 0 | $0 | 1 | $3,351 | $-3,351 |
| Lenz Robert A. | Head of R&D | 0 | $0 | 1 | $9,383 | $-9,383 |
| Pinto Joshua | President | 0 | $0 | 1 | $13,477 | $-13,477 |
| BERNS PAUL L | See Remarks | 0 | $0 | 1 | $23,468 | $-23,468 |
| Aurora Daljit Singh | Chief Strategy Officer | 0 | $0 | 2 | $321,373 | $-321,373 |
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.
Over the last 12 months, insiders at Neumora Therapeutics, Inc. Common Stock have bought $15M and sold $371,052 worth of Neumora Therapeutics, Inc. Common Stock stock.
On average, over the past 5 years, insiders at Neumora Therapeutics, Inc. Common Stock have bought $39.02M and sold $909,808 worth of stock each year.
Highest buying activity among insiders over the last 12 months: ARCH Venture Partners X, LLC (10 percent owner) — $5M. ARCH Venture Partners XII, LLC (10 percent owner) — $5M. Burow Kristina () — $5M.
The last purchase of 1,915,700 shares for transaction amount of $5M was made by Burow Kristina () on 2025‑10‑27.
| 2025-11-11 | Sale | Aurora Daljit Singh | See Remarks | 114,703 0.0741% | $2.68 | $307,026 | -23.82% | |
| 2025-10-27 | Burow Kristina | 1.92M 1.3366% | $2.61 | $5M | -19.14% | |||
| 2025-10-27 | ARCH Venture Partners XII, LLC | 10 percent owner | 1.92M 1.3366% | $2.61 | $5M | -19.14% | ||
| 2025-10-27 | ARCH Venture Partners X, LLC | 10 percent owner | 1.92M 1.3366% | $2.61 | $5M | -19.14% | ||
| 2025-02-18 | Sale | BERNS PAUL L | See Remarks | 13,871 0.0083% | $1.69 | $23,468 | -4.05% | |
| 2025-02-18 | Sale | Lenz Robert A. | Head of R&D | 5,614 0.0033% | $1.67 | $9,383 | -4.05% | |
| 2025-02-18 | Sale | Aurora Daljit Singh | Chief Strategy Officer | 8,565 0.0051% | $1.68 | $14,347 | -4.05% | |
| 2025-02-18 | Sale | Pinto Joshua | President | 8,048 0.0048% | $1.67 | $13,477 | -4.05% | |
| 2025-02-18 | Sale | Milligan Michael Lee | See Remarks | 1,978 0.0012% | $1.69 | $3,351 | -4.05% | |
| 2024-10-18 | Sale | Fust Matthew K | director | 14,049 0.0149% | $17.03 | $239,319 | -89.93% | |
| 2024-10-17 | Sale | Fust Matthew K | director | 7,739 0.0082% | $17.01 | $131,643 | -90.18% | |
| 2024-10-10 | Sale | Lenz Robert A. | Head of R&D | 8,260 0.0078% | $15.09 | $124,603 | -89.19% | |
| 2024-10-09 | Sale | Lenz Robert A. | Head of R&D | 5,563 0.0052% | $15.01 | $83,507 | -88.36% | |
| 2024-09-18 | Sale | Lenz Robert A. | Head of R&D | 10,676 0.008% | $12.09 | $129,091 | -86.36% | |
| 2024-09-17 | Sale | Lenz Robert A. | Head of R&D | 30,788 0.0226% | $11.81 | $363,736 | -85.76% | |
| 2024-09-12 | Sale | Lenz Robert A. | Head of R&D | 32,948 0.0235% | $11.43 | $376,665 | -85.67% | |
| 2023-11-14 | Burow Kristina | 3,357 0.0025% | $11.98 | $40,217 | +3.37% | |||
| 2023-11-14 | ARCH Venture Partners XII, LLC | 10 percent owner | 3,357 0.0025% | $11.98 | $40,217 | +3.37% | ||
| 2023-11-13 | Burow Kristina | 31,653 0.0232% | $11.75 | $371,923 | +2.51% | |||
| 2023-11-13 | ARCH Venture Partners XII, LLC | 10 percent owner | 31,653 0.0232% | $11.75 | $371,923 | +2.51% |
| BERNS PAUL L | See Remarks | 7405004 4.4318% | $26.21M | 0 | 1 | |
| Burow Kristina | 6046907 3.619% | $21.41M | 16 | 0 | +3% | |
| ARCH Venture Partners X, LLC | 10 percent owner | 6046907 3.619% | $21.41M | 2 | 0 | <0.0001% |
| ARCH Venture Partners XII, LLC | 10 percent owner | 6046907 3.619% | $21.41M | 15 | 0 | +3.29% |
| Lenz Robert A. | Head of R&D | 309092 0.185% | $1.09M | 0 | 6 | |
| Pinto Joshua | President | 76952 0.0461% | $272,410.08 | 0 | 1 | |
| Milligan Michael Lee | See Remarks | 22470 0.0134% | $79,543.80 | 0 | 1 | |
| Aurora Daljit Singh | See Remarks | 0 0% | $0 | 0 | 2 | |
| Fust Matthew K | director | 20100 0.012% | $71,154.00 | 0 | 2 | |
| Gosebruch Henry O | President & CEO | 15000 0.009% | $53,100.00 | 1 | 0 | <0.0001% |
$3,611,891 | 113 | 13.40% | $568.07M | |
$860,541,348 | 82 | -5.10% | $522.02M | |
Neumora Therapeutics, Inc. Common Stock (NMRA) | $63,049,419 | 31 | 2.87% | $591.5M |
$24,857,912 | 21 | -35.40% | $716.77M | |
$46,858,891 | 18 | -11.58% | $576.47M | |
$59,102,045 | 17 | 8.52% | $602.76M | |
$7,254,955 | 14 | 20.70% | $645.28M | |
$8,069,667 | 13 | -13.57% | $506.32M | |
$92,357,691 | 12 | 87.24% | $669.7M | |
$75,069,528 | 10 | 19.77% | $568.45M | |
$140,543,039 | 10 | 0.77% | $610.12M | |
$19,167,169 | 10 | 28.48% | $576.83M | |
$38,624,786 | 9 | 1.26% | $720.14M | |
$94,000,000 | 7 | -20.84% | $597.49M | |
$49,165,200 | 7 | 12.92% | $599.48M | |
$1,746,565 | 4 | -29.05% | $510.69M | |
$7,234,370 | 3 | -3.34% | $651.27M | |
$2,857,000 | 2 | -5.23% | $517.81M | |
$300,016 | 1 | -50.33% | $539.17M |
| Increased Positions | 43 | +37.07% | 7M | +13.91% |
| Decreased Positions | 45 | -38.79% | 4M | -7.57% |
| New Positions | 14 | New | 1M | New |
| Sold Out Positions | 20 | Sold Out | 2M | Sold Out |
| Total Postitions | 114 | -1.72% | 57M | +6.34% |
| Softbank Group Corp. | $10,858.00 | 3.92% | 6.54M | 0 | 0% | 2025-09-30 |
| Mic Capital Management Uk Llp | $7,405.00 | 2.67% | 4.46M | 0 | 0% | 2025-09-30 |
| Siren, L.L.C. | $7,235.00 | 2.61% | 4.36M | 0 | 0% | 2025-09-30 |
| Vanguard Group Inc | $6,722.00 | 2.42% | 4.05M | -713,736 | -14.98% | 2025-09-30 |
| Fmr Llc | $5,813.00 | 2.1% | 3.5M | -934 | -0.03% | 2025-09-30 |
| Wellcome Trust Ltd (The) As Trustee Of The Wellcome Trust | $5,493.00 | 1.98% | 3.31M | 0 | 0% | 2025-09-30 |
| Iconiq Capital, Llc | $4,248.00 | 1.53% | 2.56M | 0 | 0% | 2025-09-30 |
| Lunate Capital Ltd | $3,526.00 | 1.27% | 2.12M | 0 | 0% | 2025-09-30 |
| Millennium Management Llc | $3,334.00 | 1.2% | 2.01M | +776,856 | +63.09% | 2025-09-30 |
| T. Rowe Price Investment Management, Inc. | $3,217.00 | 1.16% | 1.94M | -164,929 | -7.84% | 2025-09-30 |